The impact of HER2-evolution on BC prognosis is unclear in the available studies, and the inclusion and exclusion criteria likewise vary between studies, but focused monitoring of patients with HER2-evolution after NAC is necessary. This evidence concerns the gene ERBB2 and breast cancer.